Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0000940603 XXXXXXXX LIVE 2 Common Stock, par value $0.0001 per share 08/07/2025 false 0002032966 00510N102 Acuren Corp 14434 Medical Complex Drive #100 Tomball TX 77377 Mariposa Acquisition IX, LLC (786) 482-6333 c/o Mariposa Capital, LLC 500 South Pointe Drive, Suite 240 Miami Beach FL 33139 0000940603 N Sir Martin E. Franklin b OO N X0 0.00 19877500.00 0.00 19877500.00 19877500.00 N 9.86 IN 1. The percentage of Common Stock beneficially owned by the Reporting Person is based on 200,598,758 shares of Common Stock and 1,000,000 shares of Series A Preferred Stock outstanding as of August 6, 2025, following the completion of the transactions contemplated by the Merger Agreement. 0002046679 N Mariposa Acquisition IX, LLC b OO N DE 0.00 19877500.00 0.00 19877500.00 19877500.00 N 9.86 OO 2. The percentage of Common Stock beneficially owned by the Reporting Person is based on 200,598,758 shares of Common Stock and 1,000,000 shares of Series A Preferred Stock outstanding as of August 6, 2025, following the completion of the transactions contemplated by the Merger Agreement. Common Stock, par value $0.0001 per share Acuren Corp 14434 Medical Complex Drive #100 Tomball TX 77377 This Amendment No. 2 ("Amendment No. 2") amends and supplements the Schedule 13D, originally filed with the Securities and Exchange Commission on February 14, 2025 and amended on May 16, 2025 (as amended, the "Statement"), relating to the common stock, par value $0.0001 per share (the "Common Stock"), of Acuren Corporation (the "Issuer"), a Delaware corporation. Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported in the Statement. Unless otherwise indicated herein, capitalized terms used but not defined in this Amendment No. 2 shall have the same meanings herein as are ascribed to such terms in the Statement. Item 4 of the Statement is supplemented as follows: On August 4, 2025, the Issuer completed the transactions contemplated by the Merger Agreement. Solely as a result of the issuance of shares of Common Stock by the Issuer in connection with the transactions contemplated by the Merger Agreement and the resulting increase in the number of shares of Common Stock outstanding, the Reporting Persons' percentage ownership in the Common Stock decreased. On August 7, 2025, the Issuer notified the Reporting Persons of the number of shares of Common Stock outstanding following the Merger. Pursuant to the terms of the Voting Agreement, the Voting Agreement automatically terminated upon receipt of the approval of the Acuren Stock Issuance at the Annual Meeting of Stockholders of the Issuer on July 31, 2025. The information set forth on the cover pages of this Schedule 13D/A is hereby incorporated by reference into this Item 5. The information set forth on the cover pages of this Schedule 13D/A is hereby incorporated by reference into this Item 5. The information set forth in Item 4 of this Statement is incorporated by reference herein. Except as otherwise described herein, to the knowledge of the Reporting Persons, only the Reporting Persons have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the Common Stock of the Issuer reported by this Statement. Not applicable Item 6 is hereby amended and supplemented by the information set forth above in Item 4 which is incorporated herein by reference. Exhibit A -- Joint Filing Agreement among the Reporting Persons, dated February 14, 2025 (incorporated by reference to Exhibit A to the Schedule 13D/A filed on May 16, 2025, by the Reporting Persons with the SEC). Exhibit B -- Placing Agreement, dated May 17, 2023, by and between the Issuer, certain of its directors and founders, Mariposa, Jefferies International Limited, Jefferies GmbH and UBS AG London Branch (incorporated by reference to Exhibit 10.8 to the Issuer's Registration Statement on Form S-4, as amended (File No. 333-282976)). Exhibit C -- Founder Insider Letter, dated May 17, 2023, by and between the Issuer, its founders and Mariposa (incorporated by reference to Exhibit 10.10 to the Issuer's Registration Statement on Form S-4, as amended (File No. 333-282976)). Exhibit D -- Certificate of Incorporation of the Issuer (incorporated by reference to Exhibit 3.1 to the Issuer's Post-Effective Amendment No. 1 to Registration Statement on Form S-4, as amended (File No. 333-282976), filed with the SEC on December 16, 2024, which contains the terms of the Series A Preferred Stock). Exhibit E -- Voting Support Agreement, by and among NV5 Global, Inc. and Mariposa Acquisition IX, LLC, dated May 14, 2025 (incorporated by reference to Exhibit 10.17 to the Issuer's Registration Statement on Form S-4, as amended (File No. 333-287888)). Sir Martin E. Franklin /s/ Sir Martin E. Franklin Sir Martin E. Franklin 08/07/2025 Mariposa Acquisition IX, LLC /s/ Sir Martin E. Franklin Sir Martin E. Franklin, its Manager 08/07/2025